Business Wire

IFF Recognized for Achieving Sustainability Leadership Throughout Transformational Year

12.1.2023 00:15:00 EET | Business Wire | Press release

Share

IFF (NYSE:IFF) today announced it has qualified for the third consecutive year as a constituent of the Dow Jones Sustainability Indices (DJSI), a family of benchmarks widely regarded as one of the world’s leading tools for investors to integrate sustainability considerations into their portfolios to increase long-term shareholder value. Named to both the 2022 World Index and the North America Index, IFF is the only company in its industry to be included.

The S&P Global Corporate Sustainability Assessment (CSA) serves as the basis for the ESG scores that power the DJSI and its prestigious list of selected companies. IFF’s total CSA score places the Company among the top 10 percent of sustainability performers in the world, as assessed from among the 2,500 largest companies in the S&P Global Broad Market Index (BMI). Similarly, IFF ranks among the top 20 percent of the 600 largest companies in the S&P Global BMI in North America.

The distinction of achieving an annual place on the DJSI – and even increasing its score from the prior year – underscores IFF’s ongoing leadership position in environmental, social and governance (ESG) management, despite significantly increasing its size and complexity following the merger with DuPont’s Nutrition & Biosciences division in 2021. The Company’s CSA disclosures scored in 2022 were the first to reflect its post-merger performance and outcomes, including those based on an increase from nearly 14,000 employees to more than 24,000, and an expanded global footprint.

IFF was also recognized for leadership in corporate transparency and performance on climate change by global environmental non-profit CDP, securing a place on its 2022 ‘A List’ for climate change for the eighth consecutive year. Based on IFF’s post-merger data reported through CDP’s 2022 Climate Change questionnaire, IFF is one of a small number of companies out of nearly 15,000 scored that were named to the ‘A List’ for climate change, based on its actions to reduce emissions, mitigate climate risks and develop the low-carbon economy. IFF also received an “A-“ in CDP’s other two categories for action to protect water security risks and forests.

“We’re very proud to be recognized by S&P Global and CDP for our ESG excellence in 2022,” said Frank Clyburn, CEO, IFF. “We credit these achievements to the laser focus of our global team—striving to be the most sustainable company we can be—guided by our ambitious Do More Good Plan. We know we have more work to do in 2023 and beyond, but these external validations continue to inspire us and are a reminder that we’re heading in the right direction.”

IFF’s Do More Good Plan is a comprehensive ESG roadmap aligned with the Company’s purpose of applying science and creativity for a better world, organized by the four strategic focus areas of Sustainable Solutions, Climate & Planetary Health, Equity & Wellbeing and Transparency & Accountability.

The 2022 DJSI and CDP recognitions follow several other competitive ESG ratings IFF received during the year, including being:

  • Awarded the 2022 EcoVadis Platinum sustainability rating for the second time, placing IFF among the top 1% of companies assessed;
  • Named for the first time to the 2022 Bloomberg Gender Equality Index for its commitment to transparency and setting a new standard in gender-related data reporting; and
  • Recertified for the second consecutive year by the Economic Dividends for Gender Equality (EDGE) at the Move level globally for its commitment to workplace diversity and intersectional issues.

Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paula Heinkel
Head of Global Communications
332-877-5339
Media.request@iff.com

Michael Bender
Director, Investor Relations
212-708-7263
Investor.Relations@iff.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release

Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye